BNT162b2

BNT162b2 is a COVID-19 genetic vaccine product developed by Pfizer and BioNTech. It uses a gene transfer platform combining messenger RNA (mRNA) and lipid nanoparticle technology to cause the recipient's cells to express the SARS-CoV-2 spike protein.¹⁾

Design

Components

FDA Ingredient Disclosure Non-medicinal contents of each dose of Pfizer. ²⁾³⁾

BNT162b2 uses a number of patented materials and products in its design and function. BioNTech in particular claims ownership of patents including:⁴⁾

Patents directed at RNA;
Patents directed at lipids/lipid nanoparticles (LNPs) and mRNA;
Patents specifically directed at pharmaceutical compositions involving LNPs and mRNA.

BioNTech patents claimed for BNT162b2 (non-exhaustive)
Title	Patent/Published Application	Applicant/Assignee	Filing Date	Status	Invention Type
Particles comprising a shell with RNA	US 10,576,146	BioNTech	March 15, 2018	Active	Lipids/LNP + mRNA
RNA formulation for immunotherapy	US 10,485,884	BioNTech	March 5, 2013	Active	Lipids/LNP + mRNA
Particles comprising a shell with RNA	US 9,950,065	BioNTech	September 26, 2013	Active	Lipids/LNP + mRNA
Particles comprising a shell with RNA	US2020/0155671	BioNTech	January 22, 2020	Pending	Lipids/LNP + mRNA
Methods and compositions for stimulating immune response	US2020/0197508	BioNTech	March 21, 2018	Pending	RNA immune response
Method for reducing immunogenicity of RNA	US2019/0153428	BioNTech	August 24, 2016	Pending	RNA immunogenicity
Formulation for administration of RNA	US2019/0321458	BioNTech	July 14, 2017	Pending	Pharmaceutical composition (PC) of Lipids/LNP + mRNA
Lipid Particle Formulations for Delivery of RNA and Water-Soluble Therapeutically Effective Compounds to a Target Cell	US2018/0263907	BioNTech	March 30, 2016	Pending	Lipids/LNP + mRNA
Stable formulations of lipids and liposomes	US2017/0273907	BioNTech	September 17, 2015	Pending	Lipids/LNP + mRNA
Method for Cellular RNA Expression	US2014/0030808	BioNTech	December 2, 2011	Pending	RNA expression
Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell	WO2016/156398	BioNTech	March 30, 2016	Published	Lipids/LNP + mRNA
Particles comprising a shell with RNA	WO2015/043613	BioNTech	September 26, 2013	Published	Lipids/LNP + mRNA
Particles comprising single stranded RNA and double stranded RNA for immunomodulation	WO2013/087083	BioNTech	December 15, 2011	Published	Lipids/LNP + mRNA

Vaccine Trials

Participants

Companies involved in the clinical trial process in any way include:

Pfizer Trial Report

https://www.fda.gov/media/144245/download

Critiques of Trial Protocols

March 29, 2023: Pfizer/BioNTech C4591001 Trial - Local & Central Testing Rates on Symptomatic Visits, by Trial Sites by OpenVAET and Josh Guetzkow
March 9, 2023: Pfizer/BioNTech C4591001 Trial - How many mathematical proofs of fraud in this trial do we need, for independent inquiries to finally start ...? by OpenVAET and Josh Guetzkow
February 27, 2023: Pfizer/BioNTech C4591001 Trial - Positive PCRs & Symptomatic Subjects by OpenVAET

Large Skewed Data Exclusions

The exclusions in the Pfizer data violate the intention to treat (ITT) principle that is part of the RCT process. https://academic.oup.com/ejo/article/37/5/457/2599978

June 8, 2021 (America's Frontline Doctors) Serious violations and manipulations of trial protocol: how Pfizer obtained FDA emergency authorization for children. https://americasfrontlinedoctors.org/frontlinenews/serious-violations-and-manipulations-of-trial-protocol-how-pfizer-obtained-fda-emergency-authorization-for-children/?fbclid=IwAR1wr4vUcJQUDrlLF08LzvvqdR_tOlcPMWxiYfT7Qm5oD7LBcdsBh4hJuTo

https://twitter.com/AotearoaMouse/status/1470541136024326145?s=20

Refusal to Release Safety Reports and Raw Data

Pfizer is trying to halt the release of documents studying its vaccine. However, due to a FOIA request submitted by Aaron Siri, some of those documents have been released.

Pfizer vaccine documents at Public Health and Medical Professionals for Transparency Documents

Emergency Use Authorization

Efficacy of BNT162b2

Efficacy in Preventing Death

Efficacy in Preventing Hospitalization

Efficacy in Preventing Infection

Efficacy in Preventing Symptoms

Efficacy in Preventing Transmission

https://www.msn.com/en-us/health/medical/study-says-pfizer-vaccine-immunity-is-so-strong-it-might-prevent-covid-19-transmission/ar-BB1cTAkA

Pharmacovigilance

Marketing

National Contracts

Pfizer has been criticized for an array of strong arm tactics while negotiating contracts for its vaccines with various nations.

https://www.legitgov.org/pfizer-demands-countries-put-military-bases-embassies-and-bank-reserves-collateral-vaccine-injury

Safety

Noteworthy Safety Events

December 10, 2021 at GreatGameIndia (article) - Pfizer vaccine batch suspended after 120 children hospitalized in Vietnam.

¹⁾ , ⁴⁾

Gaviria, M., & Kilic, B. (2020, November 12). BioNTech and Pfizer’s BNT162 Vaccine Patent Landscape. Public Citizen. https://web.archive.org/web/20220401065024/https://www.citizen.org/wp-content/uploads/BNT162-Vx-patent-landscape.pdf

²⁾

https://www.fda.gov/media/144412/download.

³⁾

https://jessicar.substack.com/p/are-red-blood-cells-agglutinating

Menu

Table of Contents